Mirtazapine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Mirtazapine: From Depression to Ohdo Syndrome and Variants
One-Sentence Summary
Mirtazapine is a NaSSA-class antidepressant; the evidence pack does not include SAHPRA-approved indication text, but its rationale data identify it as a depression treatment. The TxGNN model predicts possible efficacy for Ohdo syndrome and variants, a rare congenital syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model prediction (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no SAHPRA license text available); rationale data identify Mirtazapine as a NaSSA-class antidepressant |
| Predicted New Indication | Ohdo syndrome and variants |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the rationale data provided, Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts via antagonism of central α2-adrenergic receptors and 5-HT2/5-HT3 receptors, and its H1/5-HT2C antagonism is known to increase appetite.
Ohdo syndrome and its variants (associated with genes such as MED12, KAT6B, and CHD7) commonly present with severe feeding difficulties and failure to thrive. The theoretical link is that Mirtazapine’s appetite-stimulating property, already used off-label in some paediatric syndromic feeding-difficulty cases, could plausibly extend to this population. However, this is a pharmacological hypothesis only — no clinical trial or published case data in this evidence pack support it, and the TxGNN score, while high (0.994), reflects a model prediction rather than validated evidence.
Two additional candidates were predicted with similarly high scores but no supporting evidence: blepharophimosis–intellectual disability syndrome, Ohdo type (a sub-phenotype of Ohdo syndrome, score 99.11%), and benign paroxysmal torticollis of infancy (score 99.11%), for which the mechanistic link to Mirtazapine’s pharmacology is weaker and unestablished. All three should be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Mirtazapine is currently not marketed in South Africa according to this evidence pack, with 0 SAHPRA registrations on record. No product/dosage-form information is available to list.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: All three predicted indications are supported only by TxGNN model scores (L5), with zero clinical trials or literature identified. The drug is not currently marketed in South Africa, and TFDA/SAHPRA warning and contraindication data are marked as a Blocking data gap, preventing any initial safety assessment (S1 stage).
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI) — warnings, contraindications, drug interactions (Blocking gap)
- Confirmed mechanism of action data from DrugBank or equivalent source (High-severity gap)
- Confirmed original approved indication(s) for Mirtazapine
- Prospective case series, case reports, or trial data specifically evaluating Mirtazapine in Ohdo syndrome or related feeding-difficulty populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.